Correlation Between Eyenovia and Protalix Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both Eyenovia and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eyenovia and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eyenovia and Protalix Biotherapeutics, you can compare the effects of market volatilities on Eyenovia and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eyenovia with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eyenovia and Protalix Biotherapeutics.
Diversification Opportunities for Eyenovia and Protalix Biotherapeutics
-0.9 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Eyenovia and Protalix is -0.9. Overlapping area represents the amount of risk that can be diversified away by holding Eyenovia and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Eyenovia is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eyenovia are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Eyenovia i.e., Eyenovia and Protalix Biotherapeutics go up and down completely randomly.
Pair Corralation between Eyenovia and Protalix Biotherapeutics
Given the investment horizon of 90 days Eyenovia is expected to under-perform the Protalix Biotherapeutics. In addition to that, Eyenovia is 3.22 times more volatile than Protalix Biotherapeutics. It trades about -0.22 of its total potential returns per unit of risk. Protalix Biotherapeutics is currently generating about 0.33 per unit of volatility. If you would invest 117.00 in Protalix Biotherapeutics on September 1, 2024 and sell it today you would earn a total of 55.00 from holding Protalix Biotherapeutics or generate 47.01% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Eyenovia vs. Protalix Biotherapeutics
Performance |
| Timeline |
| Eyenovia |
| Protalix Biotherapeutics |
Eyenovia and Protalix Biotherapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Eyenovia and Protalix Biotherapeutics
The main advantage of trading using opposite Eyenovia and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eyenovia position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.| Eyenovia vs. Crinetics Pharmaceuticals | Eyenovia vs. Enanta Pharmaceuticals | Eyenovia vs. Amicus Therapeutics | Eyenovia vs. Connect Biopharma Holdings |
| Protalix Biotherapeutics vs. Corvus Pharmaceuticals | Protalix Biotherapeutics vs. Aldeyra | Protalix Biotherapeutics vs. Checkpoint Therapeutics | Protalix Biotherapeutics vs. Cidara Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Complementary Tools
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |